BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 34825282)

  • 1. Surgeon Assessment of the Technical Impact of Neoadjuvant Systemic Therapy on Operable Stage III Melanoma.
    Hieken TJ; Price DL; Piltin MA; Turner HJ; Block MS
    Ann Surg Oncol; 2022 Feb; 29(2):780-786. PubMed ID: 34825282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
    Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA
    Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).
    Ollila DW; Cirrincione CT; Berry DA; Carey LA; Sikov WM; Hudis CA; Winer EP; Golshan M
    J Am Coll Surg; 2017 Apr; 224(4):688-694. PubMed ID: 28089784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nodal basin recurrence following lymph node dissection for melanoma: implications for adjuvant radiotherapy.
    Lee RJ; Gibbs JF; Proulx GM; Kollmorgen DR; Jia C; Kraybill WG
    Int J Radiat Oncol Biol Phys; 2000 Jan; 46(2):467-74. PubMed ID: 10661355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-sectional imaging to evaluate the extent of regional nodal disease in breast cancer patients undergoing neoadjuvant systemic therapy.
    Anderson TL; Glazebrook KN; Murphy BL; Viers LD; Hieken TJ
    Eur J Radiol; 2017 Apr; 89():163-168. PubMed ID: 28267534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.
    Eggermont AM
    Recent Results Cancer Res; 2000; 157():178-89. PubMed ID: 10857171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of axillary staging and management in clinically node positive breast cancer patients treated with neoadjuvant systemic therapy: Results of a survey amongst breast cancer specialists.
    Simons JM; Maaskant-Braat AJG; Luiten EJT; Leidenius MHK; van Nijnatten TJA; Boelens PG; Koppert LB; van der Pol CC; van de Velde CJH; Audisio RA; Smidt ML
    Eur J Surg Oncol; 2020 Jan; 46(1):53-58. PubMed ID: 31434617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial.
    Burmeister BH; Henderson MA; Ainslie J; Fisher R; Di Iulio J; Smithers BM; Hong A; Shannon K; Scolyer RA; Carruthers S; Coventry BJ; Babington S; Duprat J; Hoekstra HJ; Thompson JF
    Lancet Oncol; 2012 Jun; 13(6):589-97. PubMed ID: 22575589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Axillary recurrence after lymph node excision in malignant melanoma].
    Kretschmer L; Lautenschläger C; Preusser KP; Fiedler H; Hetschko I
    Langenbecks Arch Chir; 1993; 378(1):4-11. PubMed ID: 8437502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gamma probe-directed lymphatic mapping and sentinel lymphadenectomy in primary melanoma: Reliability of the procedure and analysis of failures after long-term follow-up.
    Jacobs IA; Chevinsky AH; Swayne LC; Magidson JG; Britto EJ; Smith TJ
    J Surg Oncol; 2001 Jul; 77(3):157-64. PubMed ID: 11455551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgical outcomes of lymph node dissections for stage III melanoma after neoadjuvant systemic therapy are not inferior to upfront surgery.
    Zijlker LP; van der Burg SJC; Blank CU; Zuur CL; Klop WMC; Wouters MWMJ; van Houdt WJ; van Akkooi ACJ
    Eur J Cancer; 2023 May; 185():131-138. PubMed ID: 36989829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of routine ilioinguinal lymph node dissection for palpable inguinal melanoma nodal metastasis.
    Glover AR; Allan CP; Wilkinson MJ; Strauss DC; Thomas JM; Hayes AJ
    Br J Surg; 2014 Jun; 101(7):811-9. PubMed ID: 24752717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sentinel lymph node biopsy in melanoma patients with clinically negative regional lymph nodes--one institution's experience.
    Nowecki ZI; Rutkowski P; Nasierowska-Guttmejer A; Ruka W
    Melanoma Res; 2003 Feb; 13(1):35-43. PubMed ID: 12569283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis of treatment and prognosis of 59 cases of vulvar melanoma].
    Yuan GW; Li XG; Li N; Yao HW; Wu LY
    Zhonghua Fu Chan Ke Za Zhi; 2020 Jun; 55(6):395-401. PubMed ID: 32842246
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma.
    Lewis KD; Robinson WA; McCarter M; Pearlman N; O'Day SJ; Anderson C; Amatruda TT; Baron A; Zeng C; Becker M; Dollarhide S; Matijevich K; Gonzalez R
    J Clin Oncol; 2006 Jul; 24(19):3157-63. PubMed ID: 16809738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy.
    McMasters KM; Egger ME; Edwards MJ; Ross MI; Reintgen DS; Noyes RD; Martin RC; Goydos JS; Beitsch PD; Urist MM; Ariyan S; Sussman JJ; Davidson BS; Gershenwald JE; Hagendoorn LJ; Stromberg AJ; Scoggins CR
    J Clin Oncol; 2016 Apr; 34(10):1079-86. PubMed ID: 26858331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined PET-CT and axillary lymph node marking with radioactive iodine seeds (MARI procedure) for tailored axillary treatment in node-positive breast cancer after neoadjuvant therapy.
    Koolen BB; Donker M; Straver ME; van der Noordaa MEM; Rutgers EJT; Valdés Olmos RA; Vrancken Peeters MJTFD
    Br J Surg; 2017 Aug; 104(9):1188-1196. PubMed ID: 28524246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymph node dissection for stage III melanoma.
    Diller ML; Martin BM; Delman KA
    Surg Oncol Clin N Am; 2015 Apr; 24(2):261-77. PubMed ID: 25769711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma.
    Wagner JD; Ranieri J; Evdokimow DZ; Logan T; Chuang TY; Johnson CS; Jung SH; Wenck S; Coleman JJ
    Plast Reconstr Surg; 2003 Aug; 112(2):486-97. PubMed ID: 12900606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inguinal lymphadenectomy for stage III melanoma: a comparative study of two surgical approaches at the onset of lymphoedema.
    Bertheuil N; Sulpice L; Levi Sandri GB; Lavoué V; Watier E; Meunier B
    Eur J Surg Oncol; 2015 Feb; 41(2):215-9. PubMed ID: 25524886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.